文献速递神经肿瘤

氨基酸PET作为高级别胶质瘤患者接受Stupp方案替莫唑胺治疗后的预后工具

Amino-acid PET as a prognostic tool after post Stupp protocol temozolomide therapy in high-grade glioma patients.
PubMed 文献 · J Neurooncol · 2024-06-06

本研究评估高级别胶质瘤患者在Stupp方案替莫唑胺治疗结束后3个月内行动态[18F]FDOPA PET的预后价值。32例患者中,静态PET参数峰值肿瘤-背景比和代谢肿瘤体积(阈值分别为1.9和1.5 mL)预测6个月无进展生存的准确率最佳为84%(p=0.02),且为无进展生存的独立预测因素(p≤0.05)。结论认为替莫唑胺治疗后PET无显著摄取构成有利预后因素。

要点

  • 替莫唑胺治疗结束后3个月内行[18F]FDOPA PET可评估高级别胶质瘤预后。
  • 峰值肿瘤-背景比和代谢肿瘤体积阈值分别为1.9和1.5 mL,预测6个月无进展生存准确率84%(p=0.02)。
  • 静态PET参数是多变量分析中无进展生存的独立预测因素(p≤0.05)。

核心结论

  • 在接受Stupp方案的高级别胶质瘤患者中,替莫唑胺治疗后PET无显著摄取构成有利预后因素。

研究设计与样本

  • 分析纳入连续的高级别胶质瘤患者,均在Stupp方案替莫唑胺治疗结束后3个月内行动态[18F]FDOPA PET成像。
  • 共纳入32例患者,年龄59.4 [54.0;67.6]岁,女性13例(41%)。
  • 将静态和动态PET参数、MRI的RANO标准反应以及临床和组织分子因素与无进展生存进行相关性分析。

主要发现

  • 静态PET参数峰值肿瘤-背景比和代谢肿瘤体积(阈值分别为1.9和1.5 mL)预测6个月无进展生存的准确率最佳为84%(p=0.02)。
  • 静态PET参数在多变量分析中是无进展生存的独立预测因素(p≤0.05)。

关键数值与推荐

  • 峰值肿瘤-背景比阈值1.9和代谢肿瘤体积阈值1.5 mL用于预测6个月无进展生存,准确率84%(p=0.02)。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

PURPOSE: This study aimed to evaluate the prognostic performance of amino-acid PET in high-grade gliomas (HGG) patients at the time of temozolomide (TMZ) treatment discontinuation, after the Stupp protocol. METHODS: The analysis included consecutive HGG patients with dynamic [18F]FDOPA PET imaging within 3 months of the end of TMZ therapy, post-Stupp protocol. Static and dynamic PET parameters, responses to RANO criteria for MRI and clinical and histo-molecular factors were correlated to progression-free (PFS). RESULTS: Thirty-two patients (59.4 [54.0;67.6] years old, 13 (41%) women) were included. Static PET parameters peak tumor-to-background ratio and metabolic tumor volume (respective thresholds of 1.9 and 1.5 mL) showed the best 84% accuracies for predicting PFS at 6 months (p = 0.02). These static PET parameters were also independent predictor of PFS in multivariate analysis (p ≤ 0.05). CONCLUSION: In HGG patients having undergone a Stupp protocol, the absence of significant PET uptake after TMZ constitutes a favorable prognostic factor.

来源:J Neurooncol,查看原文。版权归原作者所有。

引用

  1. Zinsz A, Ahrari S, Becker J, et al. Amino-acid PET as a prognostic tool after post Stupp protocol temozolomide therapy in high-grade glioma patients. J Neurooncol. 2024. PMID: 38842696. doi:10.1007/s11060-024-04722-2

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。